Melody Smith, MD
Hematology · Stanford, CANPI 1790915031
Payments from drug & device makers
What this record shows
This record is dominated by grants: $18,182 of the $26,119 with a category attached, or 69.6%. Genentech, Inc. accounts for 69.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $19,014 and has fallen 97.8% since, to $427 in 2025.
Across 21 payments — averaging $1243.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$18K
- Janssen Research & Development, LLC$4K
- E.r. Squibb & Sons, L.L.C.$1K
- Novartis$925
- Gilead$551
- Bristol Myers Squibb$255
- plus $587 from 6 others
What the payments were for
- Consulting fees$6,29424%
- Grants$18,18270%
- Food & beverage$1,6436%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $18,182 |
| Janssen Research & Development, LLC | 1 | $4,290 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,329 |
| Novartis | 4 | $925 |
| Gilead(2 entities) | 5 | $551 |
| Bristol Myers Squibb | 3 | $255 |
| Sobi, Inc | 1 | $151 |
| Eli Lilly | 1 | $148 |
| Incyte Corporation | 1 | $125 |
| National Marrow Donor Program | 1 | $75 |
| Abbott | 1 | $65 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,119 in reported general payments places this provider in the 65th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 31 | $576 |
| Lorazepam | 11 | $75 |
Paid to pharmacies, not to this prescriber.
Other hematology in Stanford
- Everett MeyerStanford$2.1M
- Deepu MadduriStanford$348K
- Surbhi SidanaStanford$170K
- Michaela LiedtkeStanford$112K
- Sydney LuStanford$110K
- Saurabh DahiyaStanford$94K
- David MiklosStanford$90K
- Lori MufflyStanford$87K
- Ravindra MajetiStanford$58K
- Robert NegrinStanford$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.